AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9402173 — intervention group
Group type: COMPARATOR
Intervention: PVI 5‐FU alone
Number of subjects: 200
Study 8272992 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (8 ml) infiltrated 5 min before incision
Number of subjects: 50
Study 8272992 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 50
Study 8272992 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritramide (on-demand analgesia for 24 h)
Number of subjects: 50
Study 2888424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 2 HCl 10 mg
Number of subjects: 0
Study 2888424 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 0
Study 2888424 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 0
Study 2888424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30578215 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week PA telecoaching intervention using a step counter and smartphone app
Number of subjects: 159
Study 30578215 — intervention group
Group type: EXPERIMENTAL
Intervention: Step counter usage
Number of subjects: 159
Study 30578215 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone interface usage
Number of subjects: 159
Study 30578215 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact time groups (high, medium, low)
Number of subjects: 159
Study 30578215 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall actual usage of intervention components
Number of subjects: 159
Study 27899130 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (cephalexin)
Number of subjects: 124
Study 27899130 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 124
Study 24424708 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation for 16 weeks
Number of subjects: 138
Study 24424708 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 138
Study 24424708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 22518383 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CSE)
Number of subjects: 36
Study 22518383 — intervention group
Group type: EXPERIMENTAL
Intervention: AdhesE (ADE)
Number of subjects: 36
Study 22518383 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper SE Plus (ADP)
Number of subjects: 36
Study 22518383 — intervention group
Group type: COMPARATOR
Intervention: Bleaching
Number of subjects: 36
Study 22518383 — intervention group
Group type: COMPARATOR
Intervention: CPP‐ACP
Number of subjects: 36
Study 22518383 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching and CPP‐ACP
Number of subjects: 36
Study 20845288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular tramadol 100 mg
Number of subjects: 90
Study 20845288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin 40 µg
Number of subjects: 90
Study 20845288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin 40 µg plus intramuscular tramadol 100 mg
Number of subjects: 90
Study 20845288 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (control)
Number of subjects: 90
Study 19027564 — intervention group
Group type: EXPERIMENTAL
Intervention: Microincision cataract surgery (MICS)
Number of subjects: 74
Study 19027564 — intervention group
Group type: COMPARATOR
Intervention: Small-incision cataract surgery (SICS)
Number of subjects: 74
Study 15885513 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive remediation (Cogpack) for 15 sessions over 3 weeks
Number of subjects: 42
Study 15885513 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 42
Study 12648180 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micro g Nestorone
Number of subjects: 21
Study 12648180 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micro g Nestorone
Number of subjects: 21
Study 12648180 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micro g Nestorone
Number of subjects: 21
Study 11063500 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice a day from the day before to 3 days after mastectomy
Number of subjects: 54
Study 8931784 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg by mouth, four times daily) for 12 weeks
Number of subjects: 28
Study 8931784 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 28
Study 1298087 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 26
Study 1298087 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 26
Study 1298087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 6240749 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 micrograms of SCH 1000
Number of subjects: 10
Study 6240749 — intervention group
Group type: COMPARATOR
Intervention: 800 micrograms of fenoterol
Number of subjects: 10
Study 30852478 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod combined with alteplase
Number of subjects: 90
Study 30852478 — intervention group
Group type: COMPARATOR
Intervention: Alteplase intravenous thrombolysis
Number of subjects: 90
Study 30852478 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (0.5 mg)
Number of subjects: 90
Study 29378038 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g cashew nuts/day for 12 weeks
Number of subjects: 300
Study 29378038 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetic diet (control)
Number of subjects: 300
Study 27772661 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma-related anxiety
Number of subjects: 349
Study 27772661 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 349
Study 24709926 — intervention group
Group type: EXPERIMENTAL
Intervention: SSTP + ACT
Number of subjects: 67
Study 24709926 — intervention group
Group type: EXPERIMENTAL
Intervention: SSTP
Number of subjects: 67
Study 22668876 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN α‐2a (180 μg weekly) ± ribavirin (1000‐1200 mg daily) for 48 weeks
Number of subjects: 79
Study 20485304 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy drink containing Lactobacillus casei DN-114 001
Number of subjects: 638
Study 20485304 — intervention group
Group type: COMPARATOR
Intervention: Placebo with no live cultures
Number of subjects: 638
Study 17506733 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-propofol group (midazolam at 0.1 mg.kg(‐1) followed by propofol at 1.5 mg.kg(‐1))
Number of subjects: 40
Study 17506733 — intervention group
Group type: COMPARATOR
Intervention: Propofol group (propofol at 2.5 mg.kg(‐1))
Number of subjects: 40
Study 16163516 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (2 mg/kg, p.o.)
Number of subjects: 10
Study 16163516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12149701 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal decompression procedure
Number of subjects: 43
Study 12149701 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation (LTx)
Number of subjects: 43
Study 10591433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin (20-40 microg)
Number of subjects: 399
Study 10591433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin
Number of subjects: 399
Study 8785234 — intervention group
Group type: EXPERIMENTAL
Intervention: Swan neck catheter
Number of subjects: 40
Study 8785234 — intervention group
Group type: COMPARATOR
Intervention: Tenckhoff catheter
Number of subjects: 40
Study 2261147 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10 to 40 mg/day)
Number of subjects: 225
Study 2261147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 6360297 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposuspension
Number of subjects: 51
Study 6360297 — intervention group
Group type: COMPARATOR
Intervention: Stamey-type bladder neck suspension
Number of subjects: 51
Study 30409409 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion (500mg.day‐1 for 21 days)
Number of subjects: 90
Study 30409409 — intervention group
Group type: COMPARATOR
Intervention: Milrinone infusion (0.5μg.kg‐1.min‐1 for 21 days)
Number of subjects: 90
Study 29509598 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estradiol in softgel capsules
Number of subjects: 2
Study 29509598 — intervention group
Group type: COMPARATOR
Intervention: Vaginal pH assessment
Number of subjects: 2
Study 26857563 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic booster feedback (n=175)
Number of subjects: 346
Study 26857563 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (n=171)
Number of subjects: 346
Study 25095322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg/kg (D1)
Number of subjects: 84
Study 25095322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.5 microg/kg (D2)
Number of subjects: 84
Study 25095322 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg (M1)
Number of subjects: 84
Study 25095322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 5 mg/kg (K1)
Number of subjects: 84
Study 25095322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D1, D2)
Number of subjects: 84
Study 22257365 — intervention group
Group type: EXPERIMENTAL
Intervention: SRA+G (Standard Risk Assessment with Genetic Testing)
Number of subjects: 0
Study 22257365 — intervention group
Group type: COMPARATOR
Intervention: SRA (Standard Risk Assessment without Genetic Testing)
Number of subjects: 0
Study 22257365 — intervention group
Group type: COMPARATOR
Intervention: No-test arm (Standard Risk Assessment without Genetic Testing)
Number of subjects: 0
Study 22257365 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms (SRA+G, SRA, No-test)
Number of subjects: 0
Study 19074488 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the SNAP-IV-Teacher Form
Number of subjects: 3843
Study 17165061 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm up (light running followed by stretching and two ballet exercises)
Number of subjects: 12
Study 17165061 — intervention group
Group type: COMPARATOR
Intervention: No warm up
Number of subjects: 12
Study 17165061 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm up
Number of subjects: 12
Study 16829763 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.11 GBq (30 mCi) (131)I with the aid of rhTSH
Number of subjects: 93
Study 16829763 — intervention group
Group type: COMPARATOR
Intervention: 1.11 GBq (30 mCi) (131)I in hypothyroid state
Number of subjects: 93
Study 14520944 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (1 g/day) and clarithromycin (0.5 g/day) for 10 days along with omeprazole (40 mg/day)
Number of subjects: 66
Study 14520944 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (40 mg/day) only
Number of subjects: 66
Study 11153413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified communication (4 phone calls to GP, RF booklet provided)
Number of subjects: 1042
Study 11153413 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1042
Study 8799523 — intervention group
Group type: EXPERIMENTAL
Intervention: bretazenil (0.5 mg) + alcohol
Number of subjects: 12
Study 8799523 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam (10 mg) + alcohol
Number of subjects: 12
Study 8799523 — intervention group
Group type: EXPERIMENTAL
Intervention: bretazenil (0.5 mg)
Number of subjects: 12
Study 8799523 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam (10 mg)
Number of subjects: 12
Study 8799523 — intervention group
Group type: EXPERIMENTAL
Intervention: alcohol
Number of subjects: 12
Study 8799523 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 1622853 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus ifosfamide
Number of subjects: 0
Study 1622853 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidoxorubicin
Number of subjects: 0
Study 1622853 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone or with other polychemotherapeutic regimens without ifosfamide
Number of subjects: 0
Study 6723769 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine with 11 g aluminium phosphate
Number of subjects: 22
Study 6723769 — intervention group
Group type: COMPARATOR
Intervention: 200 mg cimetidine with water
Number of subjects: 22
Study 6723769 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone with 11 g aluminium phosphate
Number of subjects: 22
Study 6723769 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone
Number of subjects: 22
Study 29939885 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB) solution
Number of subjects: 44
Study 29939885 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 44
Study 28473423 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 125 mg subcutaneously weekly for 24 weeks
Number of subjects: 424
Study 28473423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 424
Study 26181196 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape (SpiderTech kinesiology tape precut Shoulder Spider) applied to the shoulder
Number of subjects: 16
Study 26181196 — intervention group
Group type: COMPARATOR
Intervention: Control group (no kinesiology tape)
Number of subjects: 16
Study 23131717 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab injections monthly for 3 doses
Number of subjects: 87
Study 21441163 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 8290
Study 21441163 — intervention group
Group type: COMPARATOR
Intervention: Contrast ventriculography (CNV)
Number of subjects: 8290
Study 21441163 — intervention group
Group type: COMPARATOR
Intervention: Radionuclide angiography (RNA)
Number of subjects: 8290
Study 17972070 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 60
Study 17972070 — intervention group
Group type: COMPARATOR
Intervention: Oxcarbazepine (OXCBZ)
Number of subjects: 60
Study 15947626 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) 200 U
Number of subjects: 59
Study 15947626 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) 300 U
Number of subjects: 59
Study 15947626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 12700373 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (high dose, 3.1 microg per square millimeter)
Number of subjects: 177
Study 12700373 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (low dose, 1.3 microg per square millimeter)
Number of subjects: 177
Study 12700373 — intervention group
Group type: COMPARATOR
Intervention: Control stent
Number of subjects: 177
Study 10839292 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (fluoropyrimidine-based, various routes and schedules)
Number of subjects: 614
Study 10839292 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (observation or supportive care)
Number of subjects: 614
Study 8640053 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy
Number of subjects: 933
Study 1642184 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing with extrastimuli
Number of subjects: 22
Study 1642184 — intervention group
Group type: COMPARATOR
Intervention: Short burst atrial overdrive pacing
Number of subjects: 22
Study 1642184 — intervention group
Group type: COMPARATOR
Intervention: Long burst atrial overdrive pacing
Number of subjects: 22
Study 6729582 — intervention group
Group type: EXPERIMENTAL
Intervention: Harrington instrumentation
Number of subjects: 14
Study 6729582 — intervention group
Group type: EXPERIMENTAL
Intervention: Harrington rods
Number of subjects: 14
Study 6729582 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical intervention
Number of subjects: 14
Study 6729582 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and stabilization with Harrington rods and fusion within three days after injury
Number of subjects: 14
Study 31094482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mertenil® at initial dosage of 10 mg/day (Scheme I)
Number of subjects: 702
Study 31094482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ekvamer® 5/10/10 mg/day (Scheme II)
Number of subjects: 702
Study 31094482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mertenil® 10 mg/day + Ekvator® 5/10 mg/day (Scheme III)
Number of subjects: 702
Study 31094482 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate intake in a dose of 145 mg/day (for TG >2.3 mmol/l)
Number of subjects: 702
Study 31094482 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant patients (n = 590)
Number of subjects: 702
Study 31094482 — intervention group
Group type: COMPARATOR
Intervention: Non-compliant patients
Number of subjects: 702
Study 27499527 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic oral care by the researcher
Number of subjects: 100
Study 27499527 — intervention group
Group type: COMPARATOR
Intervention: Oral care by nurses (Control)
Number of subjects: 100
Study 25567558 — intervention group
Group type: EXPERIMENTAL
Intervention: Staples
Number of subjects: 350
Study 25567558 — intervention group
Group type: COMPARATOR
Intervention: Suture
Number of subjects: 350
Study 24810310 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB, arginine and glutamine mixture alongside oral nutritional supplements (n=11)
Number of subjects: 23
Study 24810310 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional care alongside oral nutritional supplements (n=12)
Number of subjects: 23
Study 22950805 — intervention group
Group type: EXPERIMENTAL
Intervention: CVAR assessment by GPs
Number of subjects: 15
Study 20024738 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention aimed at enhancing coping skills and consistent condom use
Number of subjects: 120
Study 20024738 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study 20024738 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 120
Study 17334592 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonist (leuprolide acetate 7.5 mg/month)
Number of subjects: 97
Study 17334592 — intervention group
Group type: COMPARATOR
Intervention: Antiandrogen monotherapy (bicalutamide 50 mg q.d., nilutamide 150 mg t.i.d., flutamide 250 mg t.i.d.)
Number of subjects: 97
Study 15527426 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment (white light, 10,000 lux, 1 h daily)
Number of subjects: 102
Study 15527426 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (red light, 50 lux, 30 min daily)
Number of subjects: 102
Study 11049974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 241
Study 9277070 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (0.3 mg/kg/d) + Flucytosine (150 mg/kg/d) + Itraconazole (400 mg/d)
Number of subjects: 100
Study 9277070 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B + Flucytosine
Number of subjects: 100
Study 8417242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 68
Study 8417242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 3766376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol and Verapamil
Number of subjects: 12
Study 3766376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31090337 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Buyang Huanwu Decoction (in addition to rt-PA intravenous thrombolysis)
Number of subjects: 212
Study 31090337 — intervention group
Group type: COMPARATOR
Intervention: Control group (rt-PA intravenous thrombolysis only)
Number of subjects: 212
Study 29024233 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of low-dose aspirin (LDA) plus 4100 U of low molecular weight heparin (LMWH) subcutaneously daily
Number of subjects: 1015
Study 29024233 — intervention group
Group type: COMPARATOR
Intervention: 75 mg of low-dose aspirin (LDA) alone
Number of subjects: 1015
Study 29024233 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal D-dimer levels at all blood draw points
Number of subjects: 1015
Study 29024233 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently abnormal D-dimer or increased D-dimer after treatment
Number of subjects: 1015
Study 25592205 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized auditory cognitive training (ACT)
Number of subjects: 17
Study 24469525 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 102
Study 24469525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 22559752 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel with doxorubicin and cyclophosphamide (TAC)
Number of subjects: 100
Study 22559752 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil, doxorubicin, cyclophosphamide (FAC)
Number of subjects: 100
Study 18574553 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil administered on hemodialysis day (HD day group)
Number of subjects: 6
Study 18574553 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan medoxomil administered on non-dialysis day (non HD day group)
Number of subjects: 6
Study 18574553 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (both groups)
Number of subjects: 6
Study 18574553 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure and heart rate measurements (both groups)
Number of subjects: 6
Study 17306707 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol therapy
Number of subjects: 25
Study 17306707 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 25
Study 15352911 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose induction interferon-alpha2b (5 million units daily for 4 weeks) followed by standard dose therapy (3 million units three times a week for 44 weeks for genotype 1 or 20 weeks for non-genotype 1)
Number of subjects: 45
Study 15352911 — intervention group
Group type: COMPARATOR
Intervention: Standard dose therapy (3 million units three times a week for total treatment duration)
Number of subjects: 45